First Manhattan
SNDX icon

First Manhattan’s Syndax Pharmaceuticals SNDX Stock Holding History

First Manhattan’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,500
Closed -$12K – 1437
2018
Q3 		$12K Buy
+1,500
New +$10.7K ﹤0.01% 1204

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Manhattan's SNDX Position: Q4 2018 in Review

First Manhattan sold out of Syndax Pharmaceuticals (SNDX) in Q4 2018, closing a stake of 1,500 shares — an estimated $12K sold.

First Manhattan first reported a position in SNDX in Q3 2018 and held it in 1 quarter. The position peaked at $12K in Q3 2018. 74 funds tracked by Wall St. Rank hold SNDX as of Q4 2018.

  • First Manhattan reported no remaining Syndax Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • First Manhattan sold 1,500 Syndax Pharmaceuticals shares in Q4 2018, an estimated $12K.
  • First Manhattan first reported a position in Syndax Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • First Manhattan's Syndax Pharmaceuticals position peaked at $12K in Q3 2018.
  • 74 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2018.

Based on First Manhattan's 13F filing for Q4 2018, filed 30 Jan 2019.